This trial is active, not recruiting.

Condition plaque psoriasis
Treatments idp-118 low strength, idp-118 high strength
Phase phase 1/phase 2
Sponsor Dow Pharmaceutical Sciences
Start date June 2012
End date May 2013
Trial size 60 participants
Trial identifier NCT01670513, DPSI-IDP-118-P2-01


Subjects with a clinical diagnosis of plaque psoriasis with 10% to 20% of body surface area affected will be enrolled in the study.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety study
Intervention model parallel assignment
Masking single blind (investigator)
Primary purpose treatment
IDP-118 Low Strength
idp-118 low strength IDP-118
8 weeks
IDP-118 High Strength
idp-118 high strength IDP-118
8 weeks

Primary Outcomes

The incidence of HPA axis suppression after treatment with investigational drug product and the comparators
time frame: 8 weeks

Secondary Outcomes

To evaluate the safety and cutaneous tolerability of the two formulations and the comparators
time frame: 8 weeks

Eligibility Criteria

Male or female participants from 18 years up to 65 years old.

Inclusion Criteria: - Male or female of any race, 18 to 65 (inclusive) years of age. - Freely given verbal and written informed consent obtained from the subject. - Clinical diagnosis of psoriasis at the Screening and Baseline visits with - At least 10% - 20% of total treatable BSA involvement, and - an Investigator's Global Evaluation score of 3 or 4 ( moderate or severe) on a scale of 0 to 5 - Good general health as determined by the Investigator based on the subject's medical history and physical examination, with Screening hematology, serum chemistry, and urinalysis laboratory values within normal range limits. Exclusion Criteria: - Presence of psoriasis that was previously treated with prescription medication prior to the Screening visit and is non-responsive to corticosteroid treatment, as determined by the Investigator. - Presence of any concurrent skin condition that could interfere with the evaluation of the study drug, as determined by the Investigator. - History of adrenal disease - Female who is pregnant, nursing an infant, or planning a pregnancy during the study period.

Additional Information

Official title A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118
Description Approximately 60 subjects with a clinical diagnosis of moderate or severe psoriasis (defined as at least of 10 % - 20% treatable Body Surface Area (BSA) and an Investigator's Global Evaluation (IGE) of 3 or 4 at baseline (moderate or severe) will be enrolled in the study.
Trial information was received from ClinicalTrials.gov and was last updated in April 2013.
Information provided to ClinicalTrials.gov by Dow Pharmaceutical Sciences.